rs149654569
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_000426.4(LAMA2):c.676G>A(p.Asp226Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000168 in 1,611,048 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. D226D) has been classified as Likely benign.
Frequency
Consequence
NM_000426.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
LAMA2 | NM_000426.4 | c.676G>A | p.Asp226Asn | missense_variant | 5/65 | ENST00000421865.3 | |
LAMA2 | NM_001079823.2 | c.676G>A | p.Asp226Asn | missense_variant | 5/64 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
LAMA2 | ENST00000421865.3 | c.676G>A | p.Asp226Asn | missense_variant | 5/65 | 5 | NM_000426.4 |
Frequencies
GnomAD3 genomes AF: 0.0000461 AC: 7AN: 151908Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000359 AC: 9AN: 250816Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135552
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1459140Hom.: 0 Cov.: 30 AF XY: 0.00000964 AC XY: 7AN XY: 725976
GnomAD4 genome AF: 0.0000461 AC: 7AN: 151908Hom.: 0 Cov.: 32 AF XY: 0.0000270 AC XY: 2AN XY: 74194
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 19, 2023 | The c.676G>A (p.D226N) alteration is located in exon 5 (coding exon 5) of the LAMA2 gene. This alteration results from a G to A substitution at nucleotide position 676, causing the aspartic acid (D) at amino acid position 226 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
LAMA2-related muscular dystrophy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 26, 2022 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 226 of the LAMA2 protein (p.Asp226Asn). This variant is present in population databases (rs149654569, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with LAMA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 579005). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt LAMA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 23, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at